Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| INSMED (NASDAQ: INSM) | Delayed: 94.84 +0.80 (0.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $94.04 | 52 Week High | $19.30 | |||
| Open | $93.50 | 52 Week Low | $9.02 | |||
| Day High | $95.59 | P/E | N/A | |||
| Day Low | $93.33 | EPS | $-1.69 | |||
| Volume | 2,132,639 | |||||
